WallStreetZenWallStreetZen

NASDAQ: AYTU
Aytu Biopharma Inc Stock

$2.81+0.02 (+0.72%)
Updated Apr 22, 2024
AYTU Price
$2.81
Fair Value Price
N/A
Market Cap
$15.64M
52 Week Low
$1.38
52 Week High
$3.50
P/E
-0.73x
P/B
0.48x
P/S
0.16x
PEG
N/A
Dividend Yield
N/A
Revenue
$98.50M
Earnings
-$18.00M
Gross Margin
63.2%
Operating Margin
-17.43%
Profit Margin
-18.3%
Debt to Equity
3
Operating Cash Flow
$6M
Beta
1.24
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A

AYTU Overview

Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.

Zen Score

Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how AYTU scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

AYTU is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
AYTU is good value based on its book value relative to its share price (0.48x), compared to the US Drug Manufacturers - Specialty & Generic industry average (2.04x)
P/B vs Industry Valuation
AYTU is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more AYTU due diligence checks available for Premium users.

Be the first to know about important AYTU news, forecast changes, insider trades & much more!

AYTU News

Valuation

AYTU fair value

Fair Value of AYTU stock based on Discounted Cash Flow (DCF)
Price
$2.81
Fair Value
$8.91
Undervalued by
68.45%
AYTU is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

AYTU price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.73x
Industry
46.47x
Market
41x

AYTU price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.48x
Industry
2.04x
AYTU is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

AYTU's financial health

Profit margin

Revenue
$22.9M
Net Income
-$220.0k
Profit Margin
-1%
AYTU's Earnings (EBIT) of -$17.17M... subscribe to Premium to read more.
Interest Coverage Financials
AYTU's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$131.2M
Liabilities
$98.4M
Debt to equity
3
AYTU's short-term assets ($71.37M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AYTU's short-term assets ($71.37M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AYTU's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
AYTU's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$135.0k
Investing
-$174.0k
Financing
-$126.0k
AYTU's operating cash flow ($6.11M)... subscribe to Premium to read more.
Debt Coverage Financials

AYTU vs Pharmaceutical Stocks

TickerMarket Cap1d %P/EP/B
AYTU$15.64M+0.72%-0.73x0.48x
TLPH$15.78M-6.06%-0.72x1.12x
FLGC$14.74M+5.13%-0.21x2.30x
RDHL$16.90M-2.21%0.11x8.17x
KALA$17.83M-3.95%-0.36x2.38x

Aytu Biopharma Stock FAQ

What is Aytu Biopharma's quote symbol?

(NASDAQ: AYTU) Aytu Biopharma trades on the NASDAQ under the ticker symbol AYTU. Aytu Biopharma stock quotes can also be displayed as NASDAQ: AYTU.

If you're new to stock investing, here's how to buy Aytu Biopharma stock.

What is the 52 week high and low for Aytu Biopharma (NASDAQ: AYTU)?

(NASDAQ: AYTU) Aytu Biopharma's 52-week high was $3.50, and its 52-week low was $1.38. It is currently -19.71% from its 52-week high and 103.62% from its 52-week low.

How much is Aytu Biopharma stock worth today?

(NASDAQ: AYTU) Aytu Biopharma currently has 5,567,597 outstanding shares. With Aytu Biopharma stock trading at $2.81 per share, the total value of Aytu Biopharma stock (market capitalization) is $15.64M.

Aytu Biopharma stock was originally listed at a price of $22,600.00 in Oct 20, 2017. If you had invested in Aytu Biopharma stock at $22,600.00, your return over the last 6 years would have been -99.99%, for an annualized return of -77.66% (not including any dividends or dividend reinvestments).

How much is Aytu Biopharma's stock price per share?

(NASDAQ: AYTU) Aytu Biopharma stock price per share is $2.81 today (as of Apr 22, 2024).

What is Aytu Biopharma's Market Cap?

(NASDAQ: AYTU) Aytu Biopharma's market cap is $15.64M, as of Apr 23, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Aytu Biopharma's market cap is calculated by multiplying AYTU's current stock price of $2.81 by AYTU's total outstanding shares of 5,567,597.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.